Your browser doesn't support javascript.
loading
Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Melisi, Davide; Oh, Do-Youn; Hollebecque, Antoine; Calvo, Emiliano; Varghese, Anna; Borazanci, Erkut; Macarulla, Teresa; Merz, Valeria; Zecchetto, Camilla; Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Gandhi, Leena; Estrem, Shawn T; Benhadji, Karim A; Lanasa, Mark C; Avsar, Emin; Guba, Susan C; Garcia-Carbonero, Rocio.
Affiliation
  • Melisi D; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Università degli Studi di Verona, Verona, Italy davide.melisi@univr.it.
  • Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Hollebecque A; Institut Gustave Roussy, Villejuif, France.
  • Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Varghese A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Borazanci E; HonorHealth Research Institute, Scottsdale, Arizona, USA.
  • Macarulla T; TGen, Phoenix, Arizona, USA.
  • Merz V; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Zecchetto C; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Università degli Studi di Verona, Verona, Italy.
  • Zhao Y; Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
  • Gueorguieva I; Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Università degli Studi di Verona, Verona, Italy.
  • Man M; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Gandhi L; Eli Lilly and Company, Erl Wood, UK.
  • Estrem ST; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Benhadji KA; Eli Lilly and Company, New York, New York, USA.
  • Lanasa MC; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Avsar E; Eli Lilly and Company, New York, New York, USA.
  • Guba SC; AstraZeneca, Gaithersburg, Maryland, USA.
  • Garcia-Carbonero R; Eli Lilly and Company, New York, New York, USA.
J Immunother Cancer ; 9(3)2021 03.
Article in En | MEDLINE | ID: mdl-33688022
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Pancreatic Neoplasms / Pyrazoles / Quinolines / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / B7-H1 Antigen / Receptor, Transforming Growth Factor-beta Type I / Immune Checkpoint Inhibitors / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Aged80 Country/Region as subject: America do norte / Asia / Europa Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Pancreatic Neoplasms / Pyrazoles / Quinolines / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / B7-H1 Antigen / Receptor, Transforming Growth Factor-beta Type I / Immune Checkpoint Inhibitors / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Aged80 Country/Region as subject: America do norte / Asia / Europa Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article